Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: Results of a randomized, double-blind, vehicle-controlled study;Wirksamkeit und sicherheit von pimecrolimus-creme 1 % bei erwachsenen patienten mit vitiligo: Ergebnisse einer randomisierten, vehikel-kontrollierten doppelblind-studie

JDDG - Journal of the German Society of Dermatology

Volumn 4, Issue 11, 2006, Pages 942-946

  Dawid, Markus ^a   Veensalu, Marge ^a   Grassberger, Maximilian ^b   Wolff, Klaus ^a,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b Novartis Research Institute   (Switzerland)

^c Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Elidel ; Pimecrolimus; Vitiligo

Indexed keywords

PIMECROLIMUS; PLACEBO; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SKIN ATROPHY; TREATMENT OUTCOME; VITILIGO;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; CHILD; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; RISK ASSESSMENT; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME; VITILIGO;

EID: 33750561685     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2006.06124.x     Document Type: Article

References (14)

1. Ortonne JP, Babadoran P, Fitzpatrick TB, Mosher DB, Hori Y. Hypomelanoses and hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI: Fitzpatrick's Dermatology in General Medicine. 6th edition. New York: McGraw-Hill 2003: 839-846.
2. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38: 647-666.
3. Kostovic K, Pasic A. New treatment modalities for vitiligo: focus on topical immunomodulators. Drugs; 2005: 65: 447-459.
4. Coskun B, Saral Y, Turgut D. Topical 0.05 % clobetasol propionate versus 1 % pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15: 88-91.
5. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA,Torres-Rubalcava AB. A double-blind randomized trial of 0.1 % tacrolimus vs 0.05 % clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-585.
6. Wellington K, Noble N. Pimecrolimus: A review of its use in atopic dermatitis. Am J Clin Dermatol 2004; 5: 479-95.
7. Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1 %: a non-steroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003; 111: 1154-1168.
8. Njoo MD, Das PK, Bos JD, Westerhof W. Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol 1999; 135: 407-413.
9. Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984; 120: 631-635.
10. Kapp A, Papp K, Bingham A, Fölster-Holst R, Ortonne JP, Potter P, Gulliver W, Paul C, Molloy S, Barbier N, Hultsch T, de Prost Y. Efficacy and safety of pimecrolimus cream, a novel non-steroid anti-inflammatory, in long-term management of atopic dermatitis in infants. J Allergy Clin Immunol 2002; 110: 277-84.
11. Barba JF, Beirana A, Cohen V, Dominguez L, Duran C, Leon G, Montes de Oca F, Ocampo J, Welch O. Pimecrolimus cream 1 % is effective, well tolerated and safe in infants/children with atopic eczema of the face (conference abstract). J Eur Acad Dermatol Venereol 2003; 17 (Suppl 3): 182 (P2-35).
12. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Graeber M, Cherill R, DeProst Y for the free (children) multicenter investigator group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2.
13. Mayoral A, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: A case report. Dermatol 2003; 207: 322-323.
14. Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004; 643-655.